PhD studentship studying the Cancer Microenvironment and Immunotherapy


   Faculty of Life Sciences & Medicine

This project is no longer listed on FindAPhD.com and may not be available.

Click here to search FindAPhD.com for PhD studentship opportunities
  Dr Alan G. Ramsay  Applications accepted all year round  Funded PhD Project (UK Students Only)

About the Project

We wish to recruit motivated PhD research students to join the translational cancer / lymphoma immunology group led by Dr Alan G. Ramsay. Entry date expected to be either October 2023 or February 2024.

The group aims to study how stromal cells within the tumour microenvironment (TME) evolve during cancer progression and respond to novel immunotherapy (e.g. T cell bispecific immunotherapy) to help optimise future therapy for patients (Apollonio et al. JCI 2023). The project will provide opportunities to gain experience using innovative techniques (including tissue culture models, confocal imaging, flow cytometry, single cell RNA sequencing and multiplex spatial imaging analysis). Preparing publications and presenting at conferences will be highly encouraged and supported. The group models the cancer microenvironment using novel stroma-immune systems and analysing clinical trial patient samples.

The student will work within a research group and alongside other cancer research teams within the Guy’s Cancer Centre research floor (Innovation Hub). Generous starting stipend: £23,000 from year 1.

https://www.kcl.ac.uk/people/dr-alan-ramsay

https://www.kcl.ac.uk/research/lymphoma-immunology

https://www.kcl.ac.uk/research/facilities/nikon-imaging-centre

For further details and how to apply please visit the studentship webpage.

Biological Sciences (4)

Funding Notes

Generous starting stipend: £23,000 from year 1.

References

Recent publications from the group:
Apollonio B, et al. Tumor-activated lymph node fibroblasts suppress T cell function in diffuse large B cell lymphoma. J Clin Invest. 2023.
Ioannou N, et al. Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy. Blood. 2021 (Cover image and Commentary)
Apollonio B, et al. Understanding the Immune-Stroma Microenvironment in B Cell Malignancies for Effective Immunotherapy. Front Oncol. 2021.